Table 5.
Changes from baseline in haematological parameters and renal function
| Baseline | Eculizumab onset | 4 weeks | 12 weeks | Last follow-up | |
|---|---|---|---|---|---|
| Platelet count (×1000/µL)a | 65 (45–109) | 73 (51–113) | 166 (142–219) | 202 (157–254) | 182 (163–237) |
| Haemoglobin (g/dL)a | 8.7 (7.8–10.4) | 8.8 (8.1–9.9) | 10.5 (10–11.1) | 11 (10.2–12.3) | 11.8 (10.2–12.4) |
| Haptoglobin (mg/dL)a | 5 (0–5) | 5 (0–12) | 69 (32–115) | 118 (88–141) | 116 (86–135) |
| Serum creatinine (mg/dL)a | 3.5 (2.7–5.2) | 4.0 (3.4–5.6) | 2.3 (1.1–3.9) | 2.1 (1.1–3.5) | 2.0 (1.1–2.6) |
| eGFR (mL/min/1.73 m2)a | 18 (8.9–26) | 13 (7.7–19) | 27 (17–54) | 32 (26–71) | 34 (28–63) |
eGFR, glomerular filtrate rate.
a
Median (25th–75th percentile).